Inside Sionna’s Bid To Normalize CFTR Function
About this episode
Two leaders from Sionna Therapeutics discuss their journey in advancing therapies for cystic fibrosis.
Send us Fan Mail Two leaders from Sionna Therapeutics walk through a 15‑year journey from Genzyme science to a public company advancing NBD1‑targeted therapies in cystic fibrosis. We examine why most patients still fall short of normal CFTR, how a predictive assay de‑risks choices, and what it takes to finance, hire, and execute with patients as the North Star. Visit: sionnatx.com Visit Labtolives.com Do you want to try the quiz from this episode? Find the link on our LinkedIn profile: h...
More episodes of Lab to Lives
- Why Big Pharma Feels Like A Financial Institution & Don't Pee on Medical Gloves with Anish Shindore
- How Biotech Ideas Become Real Patient Impact w/ new co-hosts Alex and Dimitri
- Dear Pharma, Your Patient Isn’t A KPI with Mark Duman
- Audit Trails, RBQM, And Agentic AI Explained
- Why Bringing The Trial To The Patient Beats Dragging Patients To Sites
- AI Won’t Replace Writers, But Writers Who Use AI Will Outpace The Rest with Bilal Bham
Explore listener stats, chart rankings, contacts and more on the Lab to Lives podcast page.